MAXCYTE, INC. STEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - MAXCYTE INC
Financial Performance:
- Q3 earnings saw revenue growth of 27% for core revenue; PA (Professional Services/Consumables) revenue grew 20%, with instruments and licenses performing in the mid-to-high single digits.
- Net losses decreased by nearly 50% year-over-year due to improved operating leverage and tight control over operating expenses.
- Cash burn for legacy MaxSight is projected to exit the current year at $17 million, dropping to less than $10 million in 2027 following the Akron acquisition and integration synergies.
- The combined company targets a low 70s gross margin profile (MaxSight high 70s + Akron mid 60s) with $3–4 million in expected cost synergies.
- MaxSight currently expects to generate $34.5 million in total revenue for the year, having raised guidance previously.
- Cash reserves are projected to be $40–45 million post-closing, providing a runway to reach cash flow positivity by the end of 2027.
Guidance and Future Outlook:
- Management anticipates returning to growth in the second half of the previous year's period, a trend expected to continue through 2027–2029.
- Long-term goal is to achieve cash flow positivity, with management stating they are "in spitting distance" by the end of 2027.
- Revenue growth is expected to be driven by the commercialization of cell therapies, with potential for 8–9 commercial programs in the combined portfolio by late 2027/early 2028.
- Revenue synergies are projected to be minimal in 2027, with uptake beginning in 2028 and accelerating in 2029 as cross-selling to European and Asia-Pacific markets occurs.
- Management expects to sign one multi-platform large pharma license agreement annually, though sales cycles are long (approx. 24 months).
Business Segments and Product Lines:
- MaxSight (Electroporation): Core platform offers seamless workflows from research (DTX system) to clinical/commercial (GTX system); currently supports 13 clinical programs and one approved commercial product (Casgevy).
- Akron Acquisition: Doubles annual revenue, adding a leading growth factor and reagent platform; brings proprietary liquid cytokines/growth factors stable for 12+ months at refrigerated temperatures in closed, bio-welded systems.
- Secure: Provides off-target safety assessment services; revenue growth has been slower than anticipated but steady, with potential for acceleration through Akron's distribution.
- Product Expansion: The combined entity now covers the entire cell therapy workflow (non-viral, viral, expansion, activation) and supports 770+ programs (up from ~50%).
- Revenue Model Shift: Royalties from commercial products (e.g., Casgevy) will be reported as core recurring revenue; milestones remain non-recurring. Casgevy royalties contributed $1M in Q3 with significant ramp-up potential as sales scale.
Market and Competitive Landscape:
- Market funding has stabilized at ~$3.5 billion in 2025 (up 19% from 2024), shifting toward late-stage programs (e.g., Phase 3) rather than early-stage biotechs.
- Market trend shows a shift toward solid tumors (40–45% of indications), whereas historically the space was dominated by blood cancers; ex-vivo programs remain ~40% of the clinical pipeline.
- Akron differentiates from competitors like Sartorius and Thermo Fisher via unique liquid cytokine formulations in closed systems that enable automation and reduce manufacturing costs.
- The company is transitioning from a niche electroporation player to a broad cell therapy solutions provider, now embedded in 5 commercial therapies with 4 more in Phase 3 (via Akron).
Risks and Challenges:
- Early-stage biotech funding remains constrained, creating pockets of weakness for early research-stage customers, though academic clinical trials are expanding.
- Sales cycles for large pharma multi-platform licenses are lengthy (24+ months) compared to the biotech SPL model.
- Regulatory and manufacturing "stickiness" presents a challenge: once products are specified into clinical programs, switching suppliers is difficult, but gaining that initial specification requires early engagement.
- Secure's adoption rate is slow as many companies prefer to perform safety assays in-house rather than outsourcing.
Management Commentary and Tone:
- Tone is highly confident and optimistic, emphasizing the strategic fit of the Akron acquisition and the maturity of the combined organization.
- CEO Mahir Masood highlighted the successful execution of cost efficiencies and the transition to a "self-help provider" embedded in the commercial workflow.
- CFO Parmeet Ahuja emphasized strong operating leverage, noting the reduction in cash burn from historical levels of $50M+ to current levels, and the path to cash flow positivity.
- Management expressed excitement about the "win-win" synergy, noting they were not the highest bidder but the best strategic fit for Akron's global expansion.
Analyst Questions and Answers:
- Q: Strategic focus post-acquisition? A: Expansion into the full cell therapy workflow (viral and non-viral), embedding into 5 commercial therapies, and leveraging MaxSight's global sales team to expand Akron's US-centric presence to Europe and APAC.
- Q: Revenue synergies timing? A: Minimal in 2027 (lead exchange); revenue synergies expected to materialize significantly in 2028–2029 due to the long customer lifecycle.
- Q: Cost synergies? A: Targeting $3–4M in 2027 from corporate consolidation; further efficiency opportunities expected in 2028.
- Q: Market headwinds? A: Funding has shifted to late-stage programs; early-stage funding is harder to secure, but the company is seeing growth in academic trials and late-stage funding (e.g., Alatera).
- Q: Genentech partnership impact? A: Provides a stable, large pharma model complementing the biotech SPL model; contributed a bolus of instrument sales in Q3, with recurring consumable revenue to follow in 2027.
- Q: M&A strategy? A: No immediate new M&A; focus is on integrating Akron and executing on organic growth. Future M&A may be considered for specific tech additions but is not the current priority.
Other Key Points:
- Akron's leadership team (Ezekiel Zillerberg, Dave Smith) remains in place to lead operations and commercialization post-closing.
- The combined entity now supports "non-viral" and "viral" workflows, moving beyond MaxSight's original non-viral focus.
- MaxSight's SPL (Success and Progress) model, which includes royalties and milestones, is becoming a significant recurring revenue stream, particularly with Casgevy.
- Management noted that the acquisition positions the company to benefit from the anticipated approval of 2–3 more commercial cell therapies in the early 2028 timeframe.
- Company
- MAXCYTE INC
- Keywords
- MAXCYTE INC